View details of this raise on Seedstage

Greenwood Village, CO

Developing AI-powered vaccines to protect the global swine industry from deadly diseases.

• AI-Driven Vaccine Development: Kermode Biotechnologies uses AI to create next-generation vaccines and antibody treatments for swine diseases.
• Addressing Global Pork Supply Threats: The company targets diseases like African Swine Fever, which have significant economic impacts on the pork industry.
• Innovative Dual-Strategy Protocol: Combines antibody deployment and antigen vaccination to contain and prevent disease spread.
• Robust Intellectual Property Portfolio: Kermode has filed multiple patents to protect its technology, ensuring market exclusivity.
• Experienced Leadership Team: The team includes experts from prestigious institutions and leading pharmaceutical companies.

Kermode Biotechnologies is advancing its AI-driven vaccine development pipeline to address critical unmet needs in the global swine industry. The company is developing innovative immunotherapies to combat diseases such as African Swine Fever Virus, Seneca Virus A, and Swine Influenza. These diseases pose significant threats to the $60 billion global pork supply, and Kermode’s solutions aim to provide effective protection for herds worldwide. The company is leveraging AI to design vaccines and antibodies that offer rapid deployment and long-lasting immunity, addressing both preventive and emergency needs.

The funds raised will support large-scale challenge studies, clinical trials for ASFV antibody therapeutics, and expansion of manufacturing capabilities. Kermode’s leadership team, with expertise from institutions like Cornell University and companies such as Boehringer Ingelheim, is focused on creating scalable and accessible solutions for the swine industry. The company’s dual-strategy protocol combines antibody deployment and antigen vaccination to contain and prevent disease spread, positioning Kermode to capture a significant portion of the market. With a robust intellectual property portfolio, Kermode is well-positioned to maintain a competitive edge in the animal health sector.

Company Info

Kermode Biotechnologies develops AI-driven vaccines and antibody treatments to protect swine from deadly diseases, ensuring global food security.

Kermode Biotechnologies focuses on developing innovative vaccines and antibody treatments to combat swine diseases such as African Swine Fever, Senecavirus A, and Swine Influenza. Utilizing AI-driven technology, Kermode aims to provide effective immunotherapies that offer rapid protection and long-lasting immunity for swine herds. Their approach combines multiple vaccine technologies to ensure swift deployment during outbreaks, addressing a critical need in the global pork industry.

Based in Denver, Colorado, Kermode’s team includes experts from renowned institutions and pharmaceutical companies. They are committed to advancing their AI-powered vaccine development pipeline and expanding manufacturing capabilities. With a robust intellectual property portfolio, Kermode is positioned to offer scalable solutions to protect the $60 billion global pork supply, ensuring food security and economic stability.